All In Biotech

Drug Trial Radar · NCT04670809

Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies

A Randomized, Single Blind, Positive Parallel Controlled, Multicenter, Phase III Clinical Trial of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergencies

Last checked: Nov 20, 2026Latest source record: Dec 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 262 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

262

Planned (sponsor's estimate)

Start

Jul 27, 2020

Primary completion

Aug 2021

Study completion Dec 2021

Sponsor

Sponsor type
Industry
First posted
Dec 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the efficacy and safety of clevidipine for treating Hypertensive emergencies(defined as systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>120 mmHg, accompanied by acute organ damage).

Conditions

  • Hypertensive Emergency

Interventions

  • Clevidipine Butyrate InjectionDrug

    Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.

  • Ncardipine Hydrochloride InjectionDrug

    Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Target reaching rate within 30 minTime frame: 30 min

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital,Capital Medical University

    Beijing, China · Active not recruiting

  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.